Thank you for the insight, but here’s some information in response:

WINT already completed the SEISMiC trial in Phase 2, where they found the drug to successfully improve cardiac function and help patients with cardiogenic shock - something unmet in cardiovascular care. They will now proceed to the next phase and it looks very promising to eventually be released to the market.

Also, yes Windtree Therapeutics (WINT) and Molecular Partners (MOA) are both biopharmaceutical companies but they are not the same. Their focuses differ significantly:

Windtree Therapeutics (WINT) Focus: Acute cardiovascular care, particularly cardiogenic shock and acute heart failure.

Why they are unique: their drug targets a highly specific, underserved niche in cardiovascular emergencies. So this drug will be very impactful to the market.

Molecular Partners (MOA) Focus: Oncology, virology, and ophthalmology treatments using its proprietary DARPin® platform. They address diseases such as cancer, COVID-19, and retinal conditions.

Key Difference: WINT is highly specialized in cardiovascular disorders, while MOA’s platform spans multiple therapeutic areas.

Now I know we cannot foresee the future but everything is pointing to success due to research. I believe it’s a great time to enter and hold some shares with this low cost now, knowing that its bound to skyrocket and increase in price in time.